International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Spiros Miyakis, Steven A. Krilis, Guido Reber et al.|Journal of Thrombosis and Haemostasis|2006Cited by 7.1k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Paul Anantharajah Tambyah et al.|JAMA|2018Cited by 761
Whole Genome Characterization of the Mechanisms of Daptomycin Resistance in Clinical and Laboratory Derived Isolates of Staphylococcus aureusAnton Y. Peleg, George M. Eliopoulos, Spiros Miyakis et al.|PLoS ONE|2012Cited by 244
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N. A. Harris, David L. Paterson, Anton Y. Peleg et al.|Trials|2015Cited by 73